| Literature identifier | Study type | Test dosage | Effective dosage | Endocrine-mediated endpoints | Systems-level perturbations |
|---|---|---|---|---|---|
| PMID:17698168 | IVR | 500 mg/kg/day | 500 mg/kg/day | Affects morphology of hepatocytes | Hepatic endocrine-mediated perturbations |
| IVR | 1500 mg/kg/day | 1500 mg/kg/day | Affects morphology of hepatocytes | Hepatic endocrine-mediated perturbations | |
| IVR | 1500 mg/kg/day | 1500 mg/kg/day | Changes in morphology of thyroid gland | Metabolic endocrine-mediated perturbations | |
| IVR | 1500 mg/kg/day | 1500 mg/kg/day | Decrease in T3 levels | Metabolic endocrine-mediated perturbations | |
| IVR | 1500 mg/kg/day | 1500 mg/kg/day | Affects xenobiotic metabolism | Metabolic endocrine-mediated perturbations | |
| IVR | 10 mg/kg/day | 10 mg/kg/day | Decrease in T3 levels | Metabolic endocrine-mediated perturbations | |
| IVR | 10 mg/kg/day | 10 mg/kg/day | Affects morphology of hepatocytes | Hepatic endocrine-mediated perturbations | |
| PMID:26602377 | IVR | 950 mg/kg | 950 mg/kg | Decrease in T3 levels | Metabolic endocrine-mediated perturbations |
| IVR | 950 mg/kg | 950 mg/kg | Decrease in TSH levels | Metabolic endocrine-mediated perturbations | |
| IVR | 950 mg/kg | 950 mg/kg | Testicular carcinoma | Endocrine-mediated cancer;Reproductive endocrine-mediated perturbations | |
| IVR | 950 mg/kg | 950 mg/kg | Reduced sperm counts | Reproductive endocrine-mediated perturbations | |
| IVR | 950 mg/kg | 950 mg/kg | Affects steroidogenesis | Reproductive endocrine-mediated perturbations | |
| IVR | 950 mg/kg | 950 mg/kg | Decrease in T4 levels | Metabolic endocrine-mediated perturbations | |
| IVR | 750 mg/kg | - | No significant effects observed | - | |
| PMID:30565106 | IVR | 300 mg/kg | 300 mg/kg | Affects blood-testis barrier (BTB) in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations |
| IVR | 300 mg/kg | 300 mg/kg | Affects expression of estrogen receptor-alpha (ER-alpha) | Reproductive endocrine-mediated perturbations | |
| IVR | 500 mg/kg | 500 mg/kg | Affects expression of estrogen receptor-alpha (ER-alpha) | Reproductive endocrine-mediated perturbations | |
| IVR | 100 mg/kg | 100 mg/kg | Affects blood-testis barrier (BTB) in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 500 mg/kg | 500 mg/kg | Affects blood-testis barrier (BTB) in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| PMID:30844666 | IVR | 500 mg/kg/day | 500 mg/kg/day | Decrease in T4 levels | Metabolic endocrine-mediated perturbations |
| IVR | 500 mg/kg/day | 500 mg/kg/day | Increase in Thyrotropin-releasing hormone (TRH) levels | Metabolic endocrine-mediated perturbations | |
| IVR | 500 mg/kg/day | 500 mg/kg/day | Affects thyroid function | Metabolic endocrine-mediated perturbations | |
| IVR | 500 mg/kg/day | 500 mg/kg/day | Increase in TSH levels | Metabolic endocrine-mediated perturbations | |
| IVR | 50 mg/kg/day | 50 mg/kg/day | Decrease in T3 levels | Metabolic endocrine-mediated perturbations | |
| IVR | 50 mg/kg/day | 50 mg/kg/day | Affects thyroid function | Metabolic endocrine-mediated perturbations | |
| IVR | 5 mg/kg/day | 5 mg/kg/day | Changes in morphology of thyroid gland | Metabolic endocrine-mediated perturbations | |
| IVR | 5 mg/kg/day | 5 mg/kg/day | Affects thyroid function | Metabolic endocrine-mediated perturbations | |
| IVR | 500 mg/kg/day | 500 mg/kg/day | Changes in morphology of thyroid gland | Metabolic endocrine-mediated perturbations | |
| IVR | 500 mg/kg/day | 500 mg/kg/day | Decrease in T3 levels | Metabolic endocrine-mediated perturbations | |
| IVR | 50 mg/kg/day | 50 mg/kg/day | Changes in morphology of thyroid gland | Metabolic endocrine-mediated perturbations | |
| PMID:30849655 | IVTH | 0.00000001 M | 0.00000001 M | Affects liver function | Hepatic endocrine-mediated perturbations |
| IVTH | 0.0000001 M | 0.0000001 M | Affects liver function | Hepatic endocrine-mediated perturbations | |
| IVTH | 0.000001 M | 0.000001 M | Affects liver function | Hepatic endocrine-mediated perturbations | |
| PMID:35534961 | IVR | 5 mg/kg/day | 5 mg/kg/day | Affects sperm motility | Reproductive endocrine-mediated perturbations |
| IVR | 5 mg/kg/day | 5 mg/kg/day | Reduced sperm quality | Reproductive endocrine-mediated perturbations | |
| IVR | 5 mg/kg/day | 5 mg/kg/day | Abnormal sperm morphology in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 5 mg/kg/day | 5 mg/kg/day | Reduced sperm counts in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 5 mg/kg/day | 5 mg/kg/day | Decreased body weights in offspring | Developmental endocrine-mediated perturbations;Metabolic endocrine-mediated perturbations | |
| IVR | 5 mg/kg/day | 5 mg/kg/day | Affects anogenital distance | Reproductive endocrine-mediated perturbations | |
| IVR | 5 mg/kg/day | 5 mg/kg/day | Affects anogenital distance in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 5 mg/kg/day | 5 mg/kg/day | Reduced sperm counts | Reproductive endocrine-mediated perturbations | |
| IVR | 5 mg/kg/day | 5 mg/kg/day | Decreased testosterone levels in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 5 mg/kg/day | 5 mg/kg/day | Epigenomic alterations in sperm in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| PMID:35681752 | IVTH | 0.000001 - 0.000005 M | 0.000001 - 0.000005 M | Abnormal proliferation of thyroid cells | Metabolic endocrine-mediated perturbations |
| IVR | 0.002 mg/kg/day | 0.002 mg/kg/day | Induce tumor progression | Endocrine-mediated cancer | |
| IVTH | 0.000001 - 0.0000025 M | 0.000001 - 0.0000025 M | Induce cancer metastasis | Endocrine-mediated cancer | |
| IVTH | 0.000001 - 0.0000025 M | 0.000001 - 0.0000025 M | Cancer phenotype | Endocrine-mediated cancer | |
| IVTH | 0.000001 - 0.0000025 M | 0.000001 - 0.0000025 M | Altered cell cycle in thyroid cells | Metabolic endocrine-mediated perturbations | |
| PMID:36737566 | IVR | 0.1 - 2.5 mg/kg | 0.1 - 2.5 mg/kg | Changes in testicular morphology | Reproductive endocrine-mediated perturbations |
| IVR | 2.5 mg/kg | 2.5 mg/kg | Decreased testis weights | Reproductive endocrine-mediated perturbations | |
| IVR | 0.1 - 2.5 mg/kg | 0.1 - 2.5 mg/kg | Reduced sperm counts | Reproductive endocrine-mediated perturbations | |
| IVR | 2.5 mg/kg | 2.5 mg/kg | Changes in morphology of seminiferous tubules | Reproductive endocrine-mediated perturbations | |
| IVR | 2.5 mg/kg | 2.5 mg/kg | Affects expression of estrogen receptor-alpha (ER-alpha) | Reproductive endocrine-mediated perturbations | |
| IVR | 0.1 - 2.5 mg/kg | 0.1 - 2.5 mg/kg | Affects blood-testis barrier (BTB) | Reproductive endocrine-mediated perturbations | |
| PMID:38714232 | IVR | 5 mg/kg/day | 5 mg/kg/day | Increased LH levels | Reproductive endocrine-mediated perturbations |
| IVR | 5 mg/kg/day | 5 mg/kg/day | Increased prolactin levels | Reproductive endocrine-mediated perturbations | |
| IVR | 5 mg/kg/day | 5 mg/kg/day | Induce cuproptosis in ovary | Reproductive endocrine-mediated perturbations | |
| IVR | 5 mg/kg/day | 5 mg/kg/day | Oxidative stress in ovaries | Reproductive endocrine-mediated perturbations | |
| IVR | 5 mg/kg/day | 5 mg/kg/day | Increased estradiol levels | Reproductive endocrine-mediated perturbations | |
| IVR | 5 mg/kg/day | 5 mg/kg/day | Increased FSH levels | Reproductive endocrine-mediated perturbations | |
| IVR | 5 mg/kg/day | 5 mg/kg/day | Decreased testosterone levels | Reproductive endocrine-mediated perturbations | |
| IVR | 5 mg/kg/day | 5 mg/kg/day | Increased progesterone levels | Reproductive endocrine-mediated perturbations | |
| IVR | 5 mg/kg/day | 5 mg/kg/day | Affects ovarian follicles population | Reproductive endocrine-mediated perturbations | |
| IVR | 5 mg/kg/day | 5 mg/kg/day | Decreased spleen weights | Immunological endocrine-mediated perturbations | |
| IVR | 5 mg/kg/day | 5 mg/kg/day | Increased liver weights | Hepatic endocrine-mediated perturbations | |
| IVR | 5 mg/kg/day | 5 mg/kg/day | Increase in uterine weights | Reproductive endocrine-mediated perturbations | |
| IVR | 5 mg/kg/day | 5 mg/kg/day | Decreased ovarian weights | Reproductive endocrine-mediated perturbations | |
| IVR | 5 mg/kg/day | 5 mg/kg/day | Changes in ovarian morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 5 mg/kg/day | 5 mg/kg/day | Decreased inhibin-B levels | Reproductive endocrine-mediated perturbations | |
| IVR | 5 mg/kg/day | 5 mg/kg/day | Decreased Anti-Müllerian hormone (AMH) levels | Reproductive endocrine-mediated perturbations | |
| IVR | 5 mg/kg/day | 5 mg/kg/day | Abnormal estrous cycles | Reproductive endocrine-mediated perturbations |
We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.